Plant-made polio type 3 stabilized VLPs-A candidate synthetic polio vaccine

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Marsian, Johanna ^a   Fox, Helen ^b   Bahar, Mohammad W ^c   Kotecha, Abhay ^c   Fry, Elizabeth E ^c   Stuart, David I ^c,d   Macadam, Andrew J ^b   Rowlands, David J ^e   Lomonossoff, George P ^a  

^a NORWICH RESEARCH PARK   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d DIAMOND LIGHT SOURCE LTD   (United Kingdom)

^e UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; NEUTRALIZING ANTIBODY; POLIOMYELITIS VACCINE; POLYPEPTIDE; PROTEIN VP0; PROTEIN VP1; PROTEIN VP3; PROTEINASE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

GENE; GENOMICS; IMMUNIZATION; POLIOMYELITIS; RODENT; VACCINE; VIRUS PARTICLE;

AGROBACTERIUM TUMEFACIENS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CODON; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISEASE SEVERITY; DRUG CONFORMATION; DRUG MECHANISM; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; ELECTRON MICROSCOPY; HUMAN; HUMAN POLIOVIRUS 3; MOUSE; NECROSIS; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PROTEIN EXPRESSION; VACCINATION; VACCINE IMMUNOGENICITY; VIRUS PARTICLE; WILD TYPE; ANIMAL; CHEMISTRY; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MALE; METABOLISM; TOBACCO; VIROLOGY;

MUS; POLIOVIRUS;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; GENE EXPRESSION; HUMANS; MALE; MICE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES; TOBACCO;

EID: 85027512605     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-00090-w     Document Type: Article

References (51)

1. Landsteiner, K. & Popper, E. Übertragung der Poliomyelitis acuta auf Affen. Z. Immunitätsforsch. 2, 377-390 (1909).
2. Salk, J. E. et al. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am. J. Public Health Nations Health 44, 563-570 (1954).
3. Sabin, A. B. Present status of attenuated live virus poliomyelitis vaccine. Bull. N. Y. Acad. Med. 33, 17-39 (1957).
4. Minor, P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 27, 2649-2652 (2009).
5. Anis, E., et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill. 18, 20586 (2013).
6. Kitamura, N. et al. Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature 291, 547-553 (1981).
7. Racaniello, V. R. & Baltimore, D. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc. Natl. Acad. Sci. USA 78, 4887-4891 (1981).
8. Holland, J. J. & Kiehn, E. D. Specific cleavage of viral protein as steps in the synthesis and maturation of eneroviruses. Proc. Natl. Acad. Sci. USA 60, 1015-1022 (1968).
9. Basavappa, R. et al. Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 Å resolution. Protein Sci. 3, 1651-1669 (1994).
10. Holland, J. J. & Kiehn, E. D. Specific cleavage of viral proteins as steps in the synthesis and maturation of enteroviruses. Proc. Natl. Acad. Sci. USA 60, 1015-22 (1968).
11. Jacobson, M. F., Asso, J. & Baltimore, D. Further evidence on the formation of poliovirus proteins. J. Mol. Biol. 49, 657-669 (1970).
12. Hogle, J. M., Chow, M. & Filman, D. J. Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229, 1358-1365 (1985).
13. Mayer, M. M. et al. The purification of poliomyelitis virus as studied by complement fixation. J. Immunol. 78, 435-455 (1957).
14. Hummeler, K. & Hamparian, V. V. Studies on the complement fixing antigens of poliomyelitis. I. Demonstration of type and group specific antigens in native and heated viral preparations. J. Immunol. 81, 499-505 (1958).
15. Schwerdt, C. E. & Fogh, J. The ratio of physical particles per infectious unit observed for poliomyelitis viruses. Virology 4, 41-52 (1957).
16. Le Bouvier, G. L. The modification of poliovirus antigens by heat and ultraviolet light. Lancet 269, 1013-1016 (1955).
17. Grgacic, E. V. & Anderson, D. A. Virus-like particles: passport to immune recognition. Methods 40, 60-65 (2006).
18. Kushnir, N., Streatfield, S. J. & Yusibov, V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31, 58-83 (2012).
19. Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787-796 (2010).
20. Marongiu, M. E. et al. Poliovirus morphogenesis. I. Identification of 80S dissociable particles and evidence for the artifactual production of procapsids. J. Virol. 39, 341-347 (1981).
21. Filman, D. J. et al. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J. 8, 1567-1579 (1989).
22. Smith, T. J. et al. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 233, 1286-1293 (1986).
23. Tsang, S. K. et al. Stabilization of poliovirus by capsid-binding antiviral drugs is due to entropic effects. J. Mol. Biol. 296, 335-340 (2000).
24. Rombaut, B., Brioen, P. & Boeye, A. Disoxaril stabilization and immunogenicity of poliovirus procapsids. J. Gen. Virol. 71(Pt 5), 1081-1086 (1990).
25. De Colibus, L. et al. Structure elucidation of coxsackievirus A16 in complex with GPP3 informs a systematic review of highly potent capsid binders to enteroviruses. PLoS Pathog. 11, e1005165 (2015).
26. Ma, J. K., Drake, P. M. & Christou, P. The production of recombinant pharmaceutical proteins in plants. Nat. Rev. Genet. 4, 794-805 (2003).
27. Lomonossoff, G. P. & D'Aoust, M. A. Plant-produced biopharmaceuticals: a case of technical developments driving clinical deployment. Science 353, 1237-1240 (2016).
28. Lico, C., Chen, Q. & Santi, L. Viral vectors for production of recombinant proteins in plants. J. Cell. Physiol. 216, 366-377 (2008).
29. Matic, S. et al. Comparative analysis of recombinant Human Papillomavirus 8 L1 production in plants by a variety of expression systems and purification methods. Plant Biotechnol. J. 10, 410-421 (2012).
30. D'Aoust, M. A. et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol. J. 8, 607-619 (2010).
31. Thuenemann, E. C. et al. A method for rapid production of heteromultimeric protein complexes in plants: assembly of protective bluetongue virus-like particles. Plant Biotechnol. J. 11, 839-846 (2013).
32. Fox, H., Knowlson, S., Minor, P. D. & Macadam, A. J. Genetically thermo-stabilised, immunogenic poliovirus empty capsids; a strategy for non-replicating vaccines. PLoS Pathog. 13, e1006117 (2017).
33. Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. 68, 352-367 (2012).
34. De Colibus, L. et al. More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat. Struct. Mol. Biol. 21, 282-288 (2014).
35. Sainsbury, F., Liu, L. & Lomonossoff, G. P. Cowpea mosaic virus-based systems for the expression of antigens and antibodies in plants. Methods Mol. Biol. 483, 25-39 (2009).
36. Thuenemann, E. C. et al. The use of transient expression systems for the rapid production of virus-like particles in plants. Curr. Pharm. Des. 19, 5564-5573 (2013).
37. Mastronarde, D. N. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 152, 36-51 (2005).
38. Li, X. et al. Electron counting and beam-induced motion correction enable near-Atomic-resolution single-particle cryo-EM. Nat Methods 10, 584-590 (2013).
39. Kivioja, T. et al. Local average intensity-based method for identifying spherical particles in electron micrographs. J. Struct. Biol. 131, 126-134 (2000).
40. Ludtke, S. J., Baldwin, P. R. & Chiu, W. EMAN: semiautomated software for high-resolution single-particle reconstructions. J. Struct. Biol. 128, 82-97 (1999).
41. Mindell, J. A. & Grigorieff, N. Accurate determination of local defocus and specimen tilt in electron microscopy. J. Struct. Biol. 142, 334-347 (2003).
42. Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519-530 (2012).
43. Scheres, S. H. & Chen, S. Prevention of overfitting in cryo-EM structure determination. Nat. Methods 9, 853-854 (2012).
44. Pettersen, E. F. et al. UCSF chimera-A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
45. Emsley, P. et al. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
46. Debreczeni, J. E. & Emsley, P. Handling ligands with Coot. Acta Crystallogr. D Biol. Crystallogr. 68, 425-430 (2012).
47. Chen, V. B. et al. MolProbity: all-Atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
48. The PyMOL Molecular Graphics System, Version 1.8 (Schrödinger, LLC).
49. Goddard, T. D., Huang, C. C. & Ferrin, T. E. Visualizing density maps with UCSF chimera. J. Struct. Biol. 157, 281-287 (2007).
50. Singer, C. et al. Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies. J. Biol. Stand. 17, 137-150 (1989).
51. Fuchs, F. et al. Establishment of European Pharmacopoeia BRP batch 2 for inactivated poliomyelitis vaccine for in vitro D antigen assay. Pharmeuropa Bio 2003, 23-50 (2003).